{"id":71674,"date":"2026-08-05T00:08:46","date_gmt":"2026-08-04T16:08:46","guid":{"rendered":"https:\/\/flcube.com\/?p=71674"},"modified":"2026-08-05T00:08:47","modified_gmt":"2026-08-04T16:08:47","slug":"adlai-nortyes-an4035-receives-australian-regulatory-approvals-for-first-in-class-pan-rason-adc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71674","title":{"rendered":"Adlai Nortye&#8217;s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Adlai Nortye<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ANL:NASDAQ\">NASDAQ: ANL<\/a>) announced that the company&#8217;s independently developed antibody-drug conjugate (ADC) <strong>AN4035<\/strong>, which targets CEACAM5 and carries a pan-RAS(ON) inhibitor payload, has been submitted as a Clinical Trial Notification (CTN) to the Australian Therapeutic Goods Administration (TGA) and has received approval from the Human Research Ethics Committee (HREC).<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Adlai Nortye (NASDAQ: ANL)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>AN4035<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>TGA CTN approval and HREC ethical clearance<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>CEACAM5-high expressing and RAS-dependent solid tumors<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase 1<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>3 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type<\/strong>: First-in-class CEACAM5-targeting antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Payload<\/strong>: Highly potent pan-RAS(ON) inhibitor<\/li>\n\n\n\n<li><strong>Significance<\/strong>: World&#8217;s first pan-RAS(ON) antibody-drug conjugate to enter clinical development<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Precisely targets tumor sites while minimizing systemic inhibition of the RAS pathway<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: Patients with CEACAM5-high expressing, RAS-dependent solid tumors<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-plan\" class=\"wp-block-heading\">Clinical Development Plan<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The global Phase 1 clinical trial in Australia will evaluate:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Safety and tolerability<\/li>\n\n\n\n<li>Pharmacokinetics and pharmacodynamics<\/li>\n\n\n\n<li>Preliminary anti-tumor efficacy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The study will assess AN4035 both as a monotherapy and in combination with cetuximab in patients with CEACAM5-high expressing, RAS-dependent solid tumors.<\/p>\n\n\n\n<h2 id=\"h-strategic-significance\" class=\"wp-block-heading\">Strategic Significance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">RAS mutations occur in approximately 30% of all human cancers, making them one of the most common oncogenic drivers. However, direct targeting of RAS proteins has historically been challenging due to their structure and function. AN4035&#8217;s innovative approach of delivering a pan-RAS(ON) inhibitor specifically to tumor cells via CEACAM5 targeting represents a breakthrough strategy that could overcome the limitations of systemic RAS inhibition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CEACAM5 is overexpressed in various solid tumors including colorectal, gastric, pancreatic, and lung cancers, providing a broad potential addressable patient population.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global ADC Market<\/strong>: Projected to exceed $20 billion by 2030<\/li>\n\n\n\n<li><strong>RAS-Targeted Therapies<\/strong>: Significant unmet medical need with limited approved options<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: First-in-class mechanism with dual targeting approach (CEACAM5 + pan-RAS(ON))<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Global rights retained by Adlai Nortye with potential for strategic partnerships post proof-of-concept<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-company-pipeline-strategy\" class=\"wp-block-heading\">Company Pipeline Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This dual approval from Australian regulatory authorities validates our scientific approach and accelerates our clinical development timeline,&#8221; said Dr. Li Xiangdong, Chief Scientific Officer at Adlai Nortye. &#8220;AN4035 embodies our commitment to developing innovative cancer therapeutics through our proprietary ADC platform, and we&#8217;re excited to advance this promising candidate into human clinical trials.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company expects to initiate patient enrollment immediately, with initial safety data anticipated within 12-18 months. The Phase I trial will employ a dose-escalation design to determine the maximum tolerated dose and recommended Phase II dose.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adlai Nortye (NASDAQ: ANL) announced that the company&#8217;s independently developed antibody-drug conjugate (ADC) AN4035, which&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,2138,62,2139],"class_list":["post-71674","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-adlai-nortye","tag-clinical-trial-approval-initiation","tag-nasdaq-anl"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Adlai Nortye&#039;s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Adlai Nortye (NASDAQ: ANL) announced that the company&#039;s independently developed antibody-drug conjugate (ADC) AN4035, which targets CEACAM5 and carries a pan-RAS(ON) inhibitor payload, has been submitted as a Clinical Trial Notification (CTN) to the Australian Therapeutic Goods Administration (TGA) and has received approval from the Human Research Ethics Committee (HREC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71674\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adlai Nortye&#039;s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC\" \/>\n<meta property=\"og:description\" content=\"Adlai Nortye (NASDAQ: ANL) announced that the company&#039;s independently developed antibody-drug conjugate (ADC) AN4035, which targets CEACAM5 and carries a pan-RAS(ON) inhibitor payload, has been submitted as a Clinical Trial Notification (CTN) to the Australian Therapeutic Goods Administration (TGA) and has received approval from the Human Research Ethics Committee (HREC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71674\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-04T16:08:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-04T16:08:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71674#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71674\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Adlai Nortye&#8217;s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC\",\"datePublished\":\"2026-08-04T16:08:46+00:00\",\"dateModified\":\"2026-08-04T16:08:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71674\"},\"wordCount\":461,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Adlai Nortye\",\"Clinical trial approval \\\/ initiation\",\"NASDAQ: ANL\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71674#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71674\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71674\",\"name\":\"Adlai Nortye's AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-04T16:08:46+00:00\",\"dateModified\":\"2026-08-04T16:08:47+00:00\",\"description\":\"Adlai Nortye (NASDAQ: ANL) announced that the company's independently developed antibody-drug conjugate (ADC) AN4035, which targets CEACAM5 and carries a pan-RAS(ON) inhibitor payload, has been submitted as a Clinical Trial Notification (CTN) to the Australian Therapeutic Goods Administration (TGA) and has received approval from the Human Research Ethics Committee (HREC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71674#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71674\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71674#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adlai Nortye&#8217;s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adlai Nortye's AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC - Insight, China&#039;s Pharmaceutical Industry","description":"Adlai Nortye (NASDAQ: ANL) announced that the company's independently developed antibody-drug conjugate (ADC) AN4035, which targets CEACAM5 and carries a pan-RAS(ON) inhibitor payload, has been submitted as a Clinical Trial Notification (CTN) to the Australian Therapeutic Goods Administration (TGA) and has received approval from the Human Research Ethics Committee (HREC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71674","og_locale":"en_US","og_type":"article","og_title":"Adlai Nortye's AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC","og_description":"Adlai Nortye (NASDAQ: ANL) announced that the company's independently developed antibody-drug conjugate (ADC) AN4035, which targets CEACAM5 and carries a pan-RAS(ON) inhibitor payload, has been submitted as a Clinical Trial Notification (CTN) to the Australian Therapeutic Goods Administration (TGA) and has received approval from the Human Research Ethics Committee (HREC).","og_url":"https:\/\/flcube.com\/?p=71674","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-04T16:08:46+00:00","article_modified_time":"2026-08-04T16:08:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71674#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71674"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Adlai Nortye&#8217;s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC","datePublished":"2026-08-04T16:08:46+00:00","dateModified":"2026-08-04T16:08:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71674"},"wordCount":461,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Adlai Nortye","Clinical trial approval \/ initiation","NASDAQ: ANL"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71674#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71674","url":"https:\/\/flcube.com\/?p=71674","name":"Adlai Nortye's AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-04T16:08:46+00:00","dateModified":"2026-08-04T16:08:47+00:00","description":"Adlai Nortye (NASDAQ: ANL) announced that the company's independently developed antibody-drug conjugate (ADC) AN4035, which targets CEACAM5 and carries a pan-RAS(ON) inhibitor payload, has been submitted as a Clinical Trial Notification (CTN) to the Australian Therapeutic Goods Administration (TGA) and has received approval from the Human Research Ethics Committee (HREC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71674#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71674"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71674#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Adlai Nortye&#8217;s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71674"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71674\/revisions"}],"predecessor-version":[{"id":71675,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71674\/revisions\/71675"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}